Gitnux/Report 2026

Bci Industry Statistics

179Statistics
64Sources
12Sections
34mRead
Bci Industry Statistics
Samuel NorbergWritten by Samuel Norberg·Fact-checked by Maya Johansson
Published
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 39 days

01 Industry overview

The bci industry at a glance

The brain-computer interface industry remains an early-stage medical technology market, valued at $240.6 million in 2025 and moving toward broader clinical validation, commercialization and AI-enabled applications.

$240.6M[17]
Global market, 2025
15.9%[17]
Forecast CAGR, 2026–2034
31.8%[49]
Largest application share, 2025
67[9]
Implanted BCI trial participants
Market size
Fortune Business Insights estimated the global BCI market at $240.6 million in 2025 and $295.5 million in 2026. Definitions vary materially across studies because some include broader neurotechnology, neuromodulation or non-medical applications.[17]
Forecast & CAGR
The market is forecast to reach $960.8 million by 2034, representing a 15.9% CAGR from 2026 to 2034. A separate estimate from Straits Research places the 2026 market at $2.77 billion and forecasts $8.56 billion by 2034 at a 15.13% CAGR, illustrating the effect of differing market boundaries.[17][49]
Market share & regions
Publicly available market estimates identify North America as a leading regional market, supported by concentrated clinical research, venture funding and medical-device development. However, the sources reviewed did not provide a sufficiently comparable, citable regional percentage for the global BCI market.[17][9]
Segmentation
BCIs are commonly segmented by invasiveness into invasive, partially invasive and non-invasive systems; by component into hardware and software; and by use case into assistive technology, disability and rehabilitation, and other applications. Straits Research reported brain-function repair as the largest application category, with a 31.8% share in 2025.[17][49]
Trends, drivers & challenges
The main growth drivers are demand for assistive communication and rehabilitation, advances in neural decoding and AI, and increasing clinical-investment activity. The sector remains constrained by small clinical cohorts, long validation timelines, surgical and safety risks for implanted systems, signal variability and the need to demonstrate durable real-world benefit.[9][10][50]
Consumer behavior & competition
Commercial readiness is being tested primarily among people with severe movement or communication disabilities rather than mass-market consumers. One ClinicalTrials.gov study evaluated an AAC-BCI with eight users and measured usability, performance, reliability, comfort and readiness for commercialization, while competition spans implanted, wearable EEG and other non-invasive approaches.[10][17]
Regulation
In the United States, implanted BCIs for paralysis or amputation are regulated as medical devices and are generally developed through FDA investigational pathways before marketing authorization. FDA guidance specifically addresses non-clinical testing and clinical considerations for implanted BCI devices, while the Breakthrough Devices Program can provide prioritized interaction and review for qualifying devices; as of June 30, 2026, the FDA reported 1,320 total Breakthrough Device designations across device categories.[50]
Latest news
In October 2026, Butterfly Network announced a multi-year licensing agreement giving Merge Labs access to its ultrasound-on-chip technology for ultrasound-based BCI development. Butterfly stated that Merge Labs launched in January 2026 with $252 million in seed funding, highlighting continued investor interest in non-invasive or less invasive BCI architectures.[51]

02 Ranking

Top 10 Companies in the Bci Industry

The leading companies in the bci industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 10, 2026 · Next review December 10, 2026

Verdict

Neuralink leads Gitnux's 2026 bci ranking with an Overall score of 9.3, with its implantable BCI translating neural signals into computer and robotic-arm control. BrainCo is the highest-ranked non-invasive BCI technology developer at 9.2, driven by its non-invasive BCI technologies for cognitive training and digital-device interaction.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in implantable medical BCIs

    Neuralink

    US

    Ranked #1 · 9.3 · Implantable medical BCIs

    Why we picked it: It targets communication and control via implantable decoding, built for device and robotic-arm command.

    See in ranking ↓Visit neuralink.com ↗

  2. Leader in non-invasive BCI systems

    BrainCo

    US

    Ranked #2 · 9.2 · Non-invasive BCI systems

    Why we picked it: It builds non-invasive BCI systems used for cognitive training and interaction with digital devices.

    See in ranking ↓Visit brainco.tech ↗

  3. #3 overall

    Blackrock Neurotech

    US

    Ranked #3 · 8.9 · Implantable medical BCIs

    Why we picked it: It provides implantable neural interfaces and research systems with documented support for clinical research outputs.

    See in ranking ↓Visit blackrockneurotech.com ↗

Pick 1 is the #1 company overall. Pick 2 is the highest-ranked company in the top 5 that adds a new segment; no further segment places in the top 5, so pick 3 follows rank.

Full ranking

Sort by
Top 10 companies in the bci industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Neuralink

Implantable medical BCIs · US

9.3
2

BrainCo

Non-invasive BCI systems · US

9.2
3

Blackrock Neurotech

Implantable medical BCIs · US

8.9
4

Precision Neuroscience

Implantable medical BCIs · US

8.8
5

Synchron

Implantable medical BCIs · US

8.7
6

g.tec medical engineering

Integrated EEG, software and clinical BCI systems · AT

8.6
7

NeuroSky

Consumer EEG sensors and BCI platforms · US

8.4
8

EMOTIV

Wearable EEG headsets and non-invasive BCI tools · US

8.0
9

Paradromics

High-bandwidth implantable BCIs for speech and control · US

7.9
10

Cognixion

Wearable assistive BCIs for communication · US

7.6

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 10, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 10). Top 10 companies in the bci industry. In Bci Industry Statistics. Gitnux. https://gitnux.org/bci-industry-statistics/#top-companies

04 Statistics

Technology & Innovation

Technology claims in 2026 emphasize decoding accuracy gains and data scale, including 61% word accuracy for BrainQwerty and 4 million EEG hours used for model training.

AI in the bci industry

  • 61% average word accuracy was achieved by Meta’s second-generation BrainQwerty brain-computer interface, compared with 40% for its earlier version, in 2026, United States.[1]
  • 90% of seizures were correctly identified by an AI seizure-detection system in a Piramidal pilot using Cleveland Clinic EEG recordings in 2026, United States.[1]
  • More than 4 million hours of EEG data were used by AI startup Piramidal and Cleveland Clinic to train an EEG model in 2026, globally.[1]

Digital Transformation in the chemicals and materials sector (sector benchmark)

  • Among ASUG chemicals-industry members, 57% identified moving to SAP S/4HANA as a top focus area in 2025.[2]
  • Across European chemical subindustries, 65% of companies viewed digitalization as an opportunity that would significantly impact their activities in 2024.[3]
  • Among EII businesses, 68% reported adopting AI in 2024, with an estimated 10% productivity increase.[3]
  • Among ASUG chemicals-industry members, 46% ranked automation among their leading technology focus areas in 2025.[2]

Technology Adoption in the chemicals and materials sector (sector benchmark)

  • Among chemicals organizations surveyed by IBM, 53% had implemented AI for real-time process control and optimization in 2025.[4]
  • Among chemicals organizations surveyed by IBM, 49% had implemented AI for production planning and scheduling in 2025.[4]
  • Among chemicals organizations surveyed by IBM, 49% had implemented AI for quality inspection or defect detection in 2025.[4]
  • Among chemicals organizations surveyed by IBM, 45% had implemented AI for supply-chain optimization in 2025.[4]

Cloud Computing in the chemicals and materials sector (sector benchmark)

  • Across chemical-sector companies surveyed by Arthur D. Little and Cefic, 15% planned to migrate to cloud computing in coming years in 2023.[5]
  • Among EII businesses, 2% reported decreased productivity from cloud computing in 2024.[3]
  • Among EII businesses, 52% reported increased productivity from cloud computing in 2024, while 46% reported no change.[3]
  • Across chemical-sector companies surveyed by Arthur D. Little and Cefic, more than 35% had at least partially migrated to cloud computing in 2023.[5]

Big Data in the chemicals and materials sector (sector benchmark)

  • Among ASUG chemicals-industry members, 49% cited gaining actionable insights from data and analytics as a current challenge in 2025.[2]
  • Among EII businesses, 6% reported decreased productivity from big data in 2024.[3]
  • Among EII businesses, 48% reported increased productivity from big data in 2024.[3]
  • Among EII businesses, 44% reported no productivity change from big data in 2024.[3]

IoT in the chemicals and materials sector (sector benchmark)

  • Across 23 European countries, close to one-third of manufacturing firms used IoT in 2021.[6]
  • Among EII businesses, 56% reported no productivity change from IoT in 2024.[3]
  • Across European countries, 29% of firms used IoT on average in 2021.[6]
  • Among EII businesses, 44% reported increased productivity from IoT in 2024.[3]

Innovation in the bci industry

  • 49 granted BCI patents were recorded in 2015, compared with more than 100 annually from 2020 onward, globally.[7]
  • 138 BCI clinical trials, or 70.8% of the identified total, were conducted in the United States and Europe through 2024.[8]
  • 752 BCI-related patent applications, or 17.8% of the identified total, originated in the United States through August 2024.[8]
  • 23 BCI clinical trials, or 11.8% of the identified total, were conducted in China through 2024.[8]
  • 195 BCI clinical trials were identified across ClinicalTrials.gov and the Chinese Clinical Trial Registry through 2024, globally.[8]
  • 4,216 BCI-related patent applications were identified through August 2024, globally.[8]

05 Statistics

Data & Analytics

Analytics evidence centers on implanted trial exposure and outcome reporting, including 67 implanted participants identified worldwide through 2023 and 40.2 months mean participation longevity.

Data analytics in the bci industry

  • 21 research groups contributed to the worldwide implanted BCI clinical-trial evidence base through 2023.[9]
  • 31 implanted BCI participants were still active in clinical trials in the worldwide review through 2023.[9]
  • 67 people had received implanted BCIs in the 28 clinical trials identified worldwide through 2023.[9]
  • 4 electrode-array types were represented in the implanted BCI trials analyzed through 2023.[9]
  • 47 participants provided outcome data in a U.S. BCI commercial-readiness study completed in April 2026.[10]
  • 165 peer-reviewed publications were produced by implanted BCI clinical-trial programs over 25 years through 2023.[9]

Data Quality in the chemicals and materials sector (sector benchmark)

  • 44% of companies in the manufacturing survey reported AI-project failures caused by poor data quality in 2025, across surveyed manufacturers.[11]
  • 49% of supply-management organizations rated their data quality as good or excellent in 2024, based on an Institute for Supply Management survey.[12]
  • 89% of manufacturers said data use improved their decision-making processes in 2026, across the surveyed manufacturing sector.[13]
  • 42% of manufacturers had a process to verify manufacturing-data accuracy and quality in 2026, while 51% did not.[13]
  • 67% of supply-management organizations said their data quality was better or significantly better than two years earlier in 2024.[12]
  • 80% of manufacturers reported a measured value for their operational data in 2026, across the surveyed manufacturing sector.[13]

Data Governance in the chemicals and materials sector (sector benchmark)

  • 28% of manufacturers had a data-governance leader in 2026, across the Manufacturing Leadership Council survey.[13]
  • 46% of GCC chemical companies had established common data standards with collaboration partners in 2022.[14]
  • 67% of GCC chemical companies had established performance management or KPIs around digital supply chains in 2022.[14]
  • 90% of supply-management organizations agreed or strongly agreed that data governance was necessary in 2024.[12]
  • 61% of supply-management organizations had a dedicated data-governance function in 2024, based on a survey of more than 121 respondents.[12]
  • 52% of global chemical companies had established performance management or KPIs around digital supply chains in 2022.[14]

KPIs in the bci industry

  • 40.2 months was the mean participation longevity for currently active implanted BCI trial patients through 2023.[9]
  • 67 implanted BCI participants were identified worldwide through 2023 as a measure of human exposure.[9]
  • 28 implanted BCI clinical trials were identified worldwide through 2023 as a measure of clinical-development activity.[9]
  • 6 participants enrolled in Synchron’s first U.S. BCI trial, which reported one-year safety outcomes in 2024.[15]
  • 47 participants completed the AAC-BCI commercial-readiness study recorded in ClinicalTrials.gov in 2026.[10]

06 Statistics

Strategy & Growth

Growth expectations in 2026 align to a 15.9% CAGR to 2034, while clinical milestones include Neuralink’s first speech-restoration implant received in January 2024.

Growth in the bci industry

  • The global BCI market was projected to grow at a 14.1% CAGR from 2024 through 2029.[16]
  • The global BCI market was projected to grow at a 15.9% CAGR from 2026 through 2034 in the Fortune Business Insights forecast.[17]

Differentiation in the bci industry

  • The first participant received a Neuralink speech-restoration implant in January 2024.[18]
  • Neuralink’s N1 Implant is designed to decode cortically generated signals into text or speech for people with severe speech impairment.[18]

Mergers and acquisitions in the bci industry

  • Facebook agreed to acquire CTRL-Labs in September 2019 for a reported value between $500 million and $1 billion.[19]
  • Meta’s reported acquisition price for CTRL-Labs was less than $1 billion, according to a company spokesperson cited by Becker’s Hospital Review.[20]
  • CTRL-Labs had raised $67 million before Facebook’s acquisition agreement.[19]

07 Statistics

People & Workforce

Workforce signals reflect adoption constraints outside the lab, with 44.5% of U.S. chemical and pharmaceutical manufacturing roles fully hybrid in 2024.

Remote Work in the chemicals and materials sector (sector benchmark)

  • Across U.S. chemical and pharmaceutical manufacturing employers, 5.7% of positions were fully remote in 2024.[21]
  • Among U.S. energy, natural-resources and chemicals workers, 25% preferred mostly remote work in 2025.[22]
  • Among U.S. energy, natural-resources and chemicals workers, 8% preferred fully remote work in 2025.[22]
  • Across U.S. remote-capable employees, 25% worked exclusively remotely in August 2026.[23]

Hybrid Work in the chemicals and materials sector (sector benchmark)

  • Across U.S. chemical and pharmaceutical manufacturing employers, 44.5% of positions were fully hybrid in 2024.[21]
  • Across U.S. remote-capable employees, 61% preferred a hybrid work arrangement in November 2025.[23]
  • Across U.S. remote-capable employees, 54% worked in a hybrid arrangement in August 2026.[23]
  • Across U.S. hybrid employees, 48% said their team had not discussed a formal or informal collaboration plan in 2026.[23]
  • U.S. hybrid employees spent an average of 46% of their workweek on-site in 2026.[23]

Employee Engagement in the chemicals and materials sector (sector benchmark)

  • Among global managers, 22% were engaged at work in 2025, compared with 19% of non-managers.[23]
  • Across employees in the United States and Canada, 31% were engaged at work in 2025.[23]
  • Across employees worldwide, 20% were engaged at work in 2025.[23]
  • Across best-practice organizations recognized by Gallup, 70% of employees were engaged in 2025.[23]
  • Across employees in the United States, 32% were engaged at work in 2025.[23]

DEI in the bci industry

  • 31 participants were enrolled in active implanted BCI clinical trials identified worldwide through 2024.[9]
  • 21 research groups worldwide conducted 28 clinical trials involving implanted BCIs and 67 participants over 25 years through 2024.[9]

Change Management in the chemicals and materials sector (sector benchmark)

  • Across leaders in the United States, United Kingdom, Australia and Canada, change management was associated with a reported 4:1 return on investment in 2026.[24]
  • Across organizations surveyed globally, 60% said they were succeeding at business outcomes during times of change in 2024.[25]
  • Across organizations surveyed globally, 46% said they were succeeding at business outcomes during times of change in 2022.[25]
  • Across leaders in the United States, United Kingdom, Australia and Canada, 73% reported employee change fatigue in 2026.[24]
  • Across organizations surveyed globally, 56% said they were succeeding at business outcomes during times of change in 2023.[25]

08 Statistics

Customer & Sales

Customer and clinical-readiness signals include a U.S. at-home stroke trial randomizing 85 chronic stroke participants between October 2023 and August 2025.

Customer experience in the bci industry

  • 85 people with chronic stroke were randomized in a U.S. at-home BCI rehabilitation trial conducted between October 2023 and August 2025.[7]
  • 67 participants had used implanted brain-computer interfaces in 28 clinical trials worldwide through 2023, according to a review of the industry’s clinical-trial landscape.[9]

Customer acquisition in the bci industry

  • 30 adults with amyotrophic lateral sclerosis are planned for a U.S. study comparing Cognixion ONE BCI communication with existing eye-tracking devices.[26]
  • 58 post-stroke patients are targeted for enrollment in Japan’s BCI-IGNITE study of BCI-assisted upper-limb rehabilitation.[27]

09 Statistics

Marketing & Brand

Marketing research provided here is indirect to BCI product delivery, but it quantifies B2B influencer-budget and content preferences during 2024–2025.

Influencer Marketing in the chemicals and materials sector (sector benchmark)

  • Across B2B companies, 29% of marketers planned to adopt influencer marketing within the following year in a March 2025 Ipsos survey.[28]
  • Across B2B companies, 56% of marketers identified social-media posts as the most effective influencer-program content type in a September 2024 U.S. survey.[29]
  • Across B2B companies, 43% of marketers reported outstanding results from influencer programs in the 2025 B2B Influencer Marketing Report.[30]
  • Across B2B companies, 55% of marketers used creators in 2025, based on a March 2025 Ipsos survey of 1,500 marketing professionals.[28]
  • Across B2B companies, 81% of marketers had a dedicated influencer-marketing budget in a September 2024 U.S. survey of firms with at least 100 employees.[29]

10 Statistics

Operations & Execution

Operational metrics highlight the data and continuity work that underpins BCI deployments, alongside resilience testing practices reported in the survey data.

Process optimization in the bci industry

  • 37.44% of respondents identified automating part of the business impact analysis process as a preferred technology benefit in 2023.[31]
  • 58.8% of respondents were willing to embrace artificial intelligence for business continuity process automation in 2023.[31]
  • 20.26% of respondents identified real-time business impact analysis updates as a preferred technology capability in 2023.[31]
  • 37.7% of organizations used emergency notification software to enhance business continuity and resilience processes in 2023.[31]
  • 15.4% of organizations used risk-mapping software to support business continuity and resilience processes in 2023.[31]

Operational efficiency in the bci industry

  • 55.5% of resilience professionals considered technology very or extremely important in responding to disruptions in 2025.[31]
  • 62.8% of organizations reported that their disaster-recovery procedures were up to date in the BCI’s technology survey.[31]
  • 17.3% of organizations were unsure whether their disaster-recovery procedures were up to date in the BCI’s technology survey.[31]
  • 18.6% of organizations reported that their disaster-recovery procedures were not up to date in the BCI’s technology survey.[31]
  • 43.6% of organizations tested only critical systems and subsets rather than conducting full disaster-recovery tests in the BCI’s technology survey.[31]

Quality management in the bci industry

  • 35.5% of organizations coordinated and reported supply-chain disruptions across the whole enterprise in the 2023 BCI supply-chain survey.[32]
  • 26.4% of organizations did not record, measure or report performance-affecting supply-chain disruptions in 2023.[32]
  • 38.1% of organizations recorded and reported supply-chain disruptions only within certain departments or functions in 2023.[32]

Supply chain in the bci industry

  • 26% of companies stress-tested their total end-to-end supply chain annually in Europe and the United States in 2025.[33]
  • 35% of companies had appropriate detailed, up-to-date end-to-end supply-chain visibility in Europe and the United States in 2025.[33]
  • 240 supply-chain leaders in Europe and the United States participated in the BCI Global supply-chain survey in 2025.[33]
  • 85% of companies reported at least one supply-chain disruption in the BCI and Zurich survey covering 65 countries.[31]
  • 65% of companies lacked appropriate detailed, up-to-date end-to-end supply-chain visibility in Europe and the United States in 2025.[33]

Outsourcing / Offshoring in the chemicals and materials sector (sector benchmark)

  • Across 22 EU countries and Norway, 34.1% of enterprises engaged in international sourcing cited labour-cost reduction as a motivation during 2021–2023.[34]
  • Across North American specialty chemicals, 50% of customer respondents were actively pushing onshoring projects in 2025.[35]
  • Across 22 EU countries and Norway, 72.8% of enterprises engaged in international sourcing moved business functions to other EU countries during 2021–2023.[34]
  • Across North American specialty chemicals, 50% of customer respondents actively drove onshoring projects with suppliers but reported no success in 2025.[35]
  • Across North American specialty chemicals, 100% of customer respondents allocated only 0–25% of company capital expenditure to reshoring projects in 2025.[35]

11 Statistics

Finance & Pricing

Finance signals show disruption costs and resilience spending priorities, including $350,000 as the reported average cost of a severe disruption.

Cost reduction in the bci industry

  • 12% of organizations reported average significant-disruption losses of $25,000 to $50,000 during the previous five years in the 2018 BCI survey.[31]
  • 39% of organizations reported average significant-disruption losses below $25,000 during the previous five years in the 2018 BCI survey.[31]
  • 10% of organizations reported average significant-disruption losses of $100,000 to $250,000 during the previous five years in the 2018 BCI survey.[31]
  • $350,000 was the reported average cost of a severe disruption in the 2018 BCI survey.[31]
  • 9% of organizations reported average significant-disruption losses of $250,000 to $500,000 during the previous five years in the 2018 BCI survey.[31]

Financial planning in the bci industry

  • 39.6% of organizations expected their artificial-intelligence budget to be higher in 2024.[31]
  • 64.8% of organizations planning to increase resilience investment for 2024 prioritized cyber resilience as an area for higher expenditure.[31]
  • 45.7% of organizations planning to increase resilience investment for 2024 expected to raise operational-resilience expenditure.[31]
  • 48.5% of organizations planning to increase resilience investment for 2024 expected to raise their overall business continuity and resilience budget.[31]

12 Statistics

Product & Service

Product timing evidence points to a 3-year average lag from implantation to the first publication in implanted BCI research programs, alongside 6-month commercial-readiness usage.

Product development in the bci industry

  • 3 years was the average time from implantation to the first publication in implanted BCI research programs.[9]
  • 165 peer-reviewed publications were generated by implanted BCI clinical-trial programs over 25 years through 2023.[9]
  • $856 million was invested in BCI companies during the first half of 2025.[36]
  • $562 million was invested in implanted BCI technology companies in 2024.[36]
  • 15 participants were the estimated enrollment target for Neuralink’s U.S. PRIME feasibility study launched in January 2024.[37]

Product lifecycle in the bci industry

  • 3 months of communication control without recalibration was demonstrated by an implanted speech BCI participant in a published clinical study.[38]
  • 6 months was the planned usage period for participants evaluating BCI satisfaction, performance, reliability, comfort and commercialization readiness.[10]
  • 40.2 months was the mean participation longevity for patients active in implanted BCI trials through 2023.[9]
  • 47 participants completed a six-month commercial-readiness study of an augmentative BCI communication device in the United States in 2026.[10]
  • 6 participants completed the first U.S. clinical trial of Synchron’s Stentrode device by 2024.[15]

After-sales in the bci industry

  • Onsite training and ongoing education were provided by Ceribell to support customer workflow, IT integration, loyalty and retention in 2024.[39]
  • More than $2 billion was Ceribell’s estimated annual U.S. addressable market for acute-care EEG monitoring in 2024.[39]
  • More than 500 active hospital accounts used the Ceribell AI-enabled EEG system in the United States by 2024.[39]
  • More than 200,000 patients had used the Ceribell system in the United States by 2024.[39]
  • Ceribell generated recurring revenue from disposable single-patient headbands and monthly subscriptions for Clarity, recorders and its portal in 2024.[39]

Value proposition in the bci industry

  • More than 200,000 patients had received care using Ceribell’s portable, AI-enabled EEG system in the United States by 2024.[39]
  • 3 months without recalibration was reported for a speech BCI enabling stable decoding in a participant with ALS.[38]
  • 6 patients in Synchron’s U.S. trial used decoded brain signals to perform digital tasks in 2024.[15]

13 Statistics

Sustainability & Ethics

Ethics signals quantify public concern, including 83.0% of 806 respondents supporting strict regulation of brain-computer interfaces in 2024.

Ethics in the bci industry

  • 40.1% of 806 UK respondents believed brain-computer interfaces could exacerbate social inequalities in a 2024 survey.[7]
  • 67% of 144 BCI ethics-survey respondents disagreed with attempting an intervention when a non-communicative patient’s legal representative withheld consent, in a 2013 study.[7]
  • 57.4% of 806 UK respondents considered hacking risks significant for brain-computer interfaces in a 2024 survey.[7]
  • 83.0% of 806 UK respondents supported strict regulation of brain-computer interfaces in a 2024 survey.[7]
  • 64.9% of 806 UK respondents supported BCI use for people with disabilities in a 2024 survey.[7]

15 Statistics

Globalization & Expansion

Globalization signals show both scale and trial geography, including 138 BCI clinical trials in the United States and Europe through 2024.

Globalization in the bci industry

  • $2.62 billion was the projected global brain-machine interface market size in 2024.[45]
  • The global BCI market was valued at $262 million in 2024 in the MarketsandMarkets estimate.[16]
  • North America accounted for approximately 42% of global brain-computer-interface hardware market revenue in 2024.[46]
  • $12.40 billion was the projected global brain-machine interface market size for 2034.[45]
  • The global BCI market was projected to reach $506 million by 2029 in the MarketsandMarkets forecast.[16]

Cultural adaptation in the bci industry

  • Europe represented 51% of surveyed implantable-neural-device trials involving post-trial access research.[7]
  • Clinical BCI trials were conducted predominantly in North America, representing 46% of surveyed implantable-neural-device trials.[7]

Stakeholder management in the bci industry

  • The implanted BCI trials identified in the review had produced 165 peer-reviewed publications over 25 years.[9]
  • The mean participation longevity for patients currently active in implanted BCI trials was 40.2 months.[9]
  • ClinicalTrials.gov BCI studies were 88.1% intervention studies in a global registration analysis.[47]
  • Thirty-one participants were active in implanted BCI clinical trials identified in the 2024 global review.[9]
  • Twenty-one research groups worldwide had conducted implanted BCI clinical trials involving 67 participants, according to a 2024 review.[9]

Distribution channels in the bci industry

  • Synchron’s second mission targets 500 million people with cognitive decline through general-cognition models.[48]
  • Synchron’s first mission targets 15 million people with motor impairment through its BCI technology.[48]

Key questions about the bci industry

What is the BCI market size in 2025 and 2026?
Fortune Business Insights estimated the global BCI market at $240.6 million in 2025 and $295.5 million in 2026.
How fast is the BCI market expected to grow from 2026 to 2034?
The market is forecast to reach $960.8 million by 2034, representing a 15.9% CAGR from 2026 to 2034.
Which companies lead the bci industry?
Neuralink leads Gitnux's 2026 bci ranking with an Overall score of 9.3, with its implantable BCI translating neural signals into computer and robotic-arm control. BrainCo is the highest-ranked non-invasive BCI technology developer at 9.2, driven by its non-invasive BCI technologies for cognitive training and digital-device interaction.
What technology shift is shaping BCI R&D in 2026?
Non-invasive architectures attract new capital, and AI advances are tied to improved decoding and personalization.
How concentrated is the market by geography, based on public estimates?
Publicly available estimates identify North America as a leading regional market, but they did not provide a sufficiently comparable, citable global regional percentage.
What constraint most often slows adoption of implanted BCIs?
The sector remains constrained by small clinical cohorts, long validation timelines, and signal variability that requires durable real-world benefit.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 10). Bci Industry Statistics. Gitnux. https://gitnux.org/bci-industry-statistics
MLA
Samuel Norberg. "Bci Industry Statistics." Gitnux, 10 Nov 2026, https://gitnux.org/bci-industry-statistics.
Chicago
Samuel Norberg. 2026. "Bci Industry Statistics." Gitnux. https://gitnux.org/bci-industry-statistics.

Sources & references

64 sources cited across this report

  1. tomshardware.com
  2. s3.us-east-1.amazonaws.com
  3. monitor-industrial-ecosystems.ec.europa.eu
  4. ibm.com
  5. cefic.org
  6. oecd.org
  7. pmc.ncbi.nlm.nih.gov
  8. link.springer.com
  9. nature.com
  10. clinicaltrials.gov
  11. dnb.com
  12. utah.ismworld.org
  13. manufacturingleadershipcouncil.com
  14. gpca.org.ae
  15. medtechdive.com
  16. marketsandmarkets.com
  17. fortunebusinessinsights.com
  18. neuralink.com
  19. techcrunch.com
  20. beckershospitalreview.com
  21. naceweb.org
  22. kpmg.com
  23. gallup.com
  24. deloitte.com
  25. sia-partners.com
  26. alongside-als.org
  27. jrct.mhlw.go.jp
  28. business.linkedin.com
  29. marketingprofs.com
  30. toprankmarketing.com
  31. thebci.org
  32. sgs.com
  33. bciglobal.com
  34. ec.europa.eu
  35. 5418442.fs1.hubspotusercontent-na1.net
  36. ttp.com
  37. stellatrials.com
  38. hopkinsmedicine.org
  39. sec.gov
  40. gao.gov
  41. enhesa.com
  42. ismg-cdn.nyc3.cdn.digitaloceanspaces.com
  43. trustarc.com
  44. chemtrec.com
  45. det.dco.org
  46. marketresearchreports.com
  47. cs.china-cmd.org
  48. synchron.com
  49. straitsresearch.com
  50. fda.gov
  51. butterflynetwork.com
  52. brainco.tech
  53. blackrockneurotech.com
  54. precisionneuro.io
  55. gtec.at
  56. neurosky.com
  57. emotiv.com
  58. paradromics.com
  59. cognixion.com
  60. ctv.veeva.com
  61. clinicaltrials.gg
  62. ir.butterflynetwork.com
  63. earnings-documents-prod.s3.amazonaws.com
  64. insidebci.com